[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336149-105":59,"doc-detail-336149-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","microfluidics-based-technologies-for-the-assessment-of-castration-resistant-prostate-cancer","Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer","","Castration-resistant prostate cancer remains a major clinical challenge because patients do not respond to existing hormone therapies. Standard care often relies on chemotherapy, radiation therapy, and additional drugs to control metastatic growth, creating a need for improved diagnostics and management tools. Conventional approaches depend heavily on animal models and 2D in vitro systems, which struggle to reproduce the dynamic tumor microenvironment and can misestimate drug efficacy and adverse effects. Microfluidics offers promising alternatives including cell assessment, circulating tumor cell isolation, and tumor-on-a-chip models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microfluidics-based-technologies-for-the-assessment-of-castration-resistant-prostate-cancer/336149/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microfluidics-based-technologies-for-the-assessment-of-castration-resistant-prostate-cancer/336149.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is castration-resistant prostate cancer considered a difficult clinical problem?","Question",{"text":112,"@type":113},"Patients show no response to existing hormone therapies, so cancer continues despite androgen-directed treatment strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations do animal models and 2D in vitro technologies have for prostate cancer research?",{"text":117,"@type":113},"They often fail to reproduce the dynamic tumor microenvironment, which can lead to discrepancies in how drugs work and what side effects they may cause clinically.",{"name":119,"@type":110,"acceptedAnswer":120},"How do microfluidics-based technologies support assessment and research in castration-resistant prostate cancer?",{"text":121,"@type":113},"They enable evaluation of prostate cancer cells, isolation of circulating tumor cells, and study of cell behavior using tumor-on-a-chip models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336149,1790508456,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","cells  \nReview  \nMicrofluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer  \nAmel Sassi 1 and Lidan You 1,2,3, *  \nCitation: Sassi, A.; You, L. Microfluidics-Based Technologies for the Assessment of CastrationResistant Prostate Cancer. Cells 2024, 13, 575. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells13070575  \nAcademic Editor: Roger Schneiter  \nReceived: 22 February 2024  \nRevised: 22 March 2024  \nAccepted: 23 March 2024  \nPublished: 26 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada; [amel.sassi@mail.utoronto.ca](amel.sassi@mail.utoronto.ca)  \n2 Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada  \n3 Department of Mechanical and Materials Engineering, Queen’s University, Kingston, ON K7L 2V9, Canada  \n* [Correspondence: youlidan@mie.utoronto.ca](Correspondence: youlidan@mie.utoronto.ca)  \nAbstract: Castration-resistant prostate cancer remains a significant clinical challenge, wherein patients display no response to existing hormone therapies. The standard of care often includes aggressive treatment options using chemotherapy, radiation therapy and various drugs to curb the growth of additional metastases. As such, there is a dire need for the development of innovative technologies for both its diagnosis and its management. Traditionally, scientific exploration of prostate cancer and its treatment options has been heavily reliant on animal models and two-dimensional (2D) in vitro technologies. However, both laboratory tools often fail to recapitulate the dynamic tumor microenvironment, which can lead to discrepancies in drug efficacy and side effects in a clinical setting. In light of the limitations of traditional animal models and 2D in vitro technologies, the emergence of microfluidics as a tool for prostate cancer research shows tremendous promise. Namely, microfluidics-based technologies have emerged as powerful tools for assessing prostate cancer cells, isolating circulating tumor cells, and examining their behaviour using tumor-on-a-chip models. As such, this review aims to highlight recent advancements in microfluidics-based technologies for the assessment of castration-resistant prostate cancer and its potential to advance current understanding and to improve therapeutic outcomes.  \nKeywords: microfluidics; castration-resistant prostate cancer; circulating tumor cells; biomarkers; tumor-on-a-chip  \n1. Introduction  \n1.1. Prostate Cancer  \nProstate cancer (PCa) is the most prevalent non-cutaneous cancer across Europe and North America, with an estimated 1 in 8 men being diagnosed during their lifetime [1] . It is also the second leading cause of cancer-related deaths among men in the United States, accounting for over 34,500 deaths in 2022 [2] PCa is characterized by the abnormal division of cells, leading to an irregular growth of the prostate gland. Diagnosis involves the use of both the digital rectal examination and PCa screening using prostate-specific antigen (PSA) [3] .  \nFor localized PCa, the standard treatment options include prostatectomy or radiation to remove malignant cells [4,5] . However, in more advanced cases, such as metastatic disease or recurrent PCa, androgen deprivation therapy (ADT) is utilized [6,7] .  \n1.2. Castration-Resistant Prostate Cancer  \nADT, also known as hormone therapy, targets the overexpression of the androgen receptor (AR) on the prostate in PCa patients [8] . This overexpression, driven by AR amplification, increases the binding of ligands to the","cbCaivKdefkgCUOP","https://ap.wps.com/l/cbCaivKdefkgCUOP","pdf",5883053,22,"English","# Introduction\n## Prostate Cancer\n## Castration-Resistant Prostate Cancer","[{\"question\":\"Why is castration-resistant prostate cancer considered a difficult clinical problem?\",\"answer\":\"Patients show no response to existing hormone therapies, so cancer continues despite androgen-directed treatment strategies.\"},{\"question\":\"What limitations do animal models and 2D in vitro technologies have for prostate cancer research?\",\"answer\":\"They often fail to reproduce the dynamic tumor microenvironment, which can lead to discrepancies in how drugs work and what side effects they may cause clinically.\"},{\"question\":\"How do microfluidics-based technologies support assessment and research in castration-resistant prostate cancer?\",\"answer\":\"They enable evaluation of prostate cancer cells, isolation of circulating tumor cells, and study of cell behavior using tumor-on-a-chip models.\"}]","Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer | PDF",1790013826,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34f4ea34a5edc3a96d8f995606284bd4.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af92f0883f7bce9c63bf793e88c74d25.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26713377c6349f67288a23870e4374aa.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8c99af217ebf139b78c2687007f2065.webp",980,1385]